SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models

BACKGROUND: Targeted estrogen receptor degradation has been approved to effectively treat ER + breast cancers. Due to the poor bioavailability of fulvestrant, the first generation of SERD, many efforts were made to develop oral SERDs. With the approval of Elacestrant, oral SERDs demonstrated superio...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Feng, Yang, Guimei, Xue, Liting, Liu, Yajing, Guo, Yao, Zhu, Ji, Yuan, Linlin, Gu, Peng, Tang, Feng, Shan, Jinwen, Tang, Renhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426190/
https://www.ncbi.nlm.nih.gov/pubmed/37580832
http://dx.doi.org/10.1186/s13058-023-01695-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426190/
https://www.ncbi.nlm.nih.gov/pubmed/37580832
http://dx.doi.org/10.1186/s13058-023-01695-4

Ejemplares similares